Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR t cell therapy: how safe is it years later?

NCT ID NCT06508775

Disease control Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma, lymphoma, or leukemia. Researchers will track side effects, cancer return, and overall health for years. The goal is to understand the long-term safety and effectiveness of this treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CAR T cells (immune cells engineered to target cancer)
What this could lead to
If successful, this could confirm that CAR T cell therapy remains safe and effective for years, supporting its use as a long-term treatment for certain blood cancers and melanoma.
What could go wrong
This is a long-term follow-up study, not a new treatment test. It may reveal late side effects or loss of effectiveness over time. The small size (40 people) limits how much we can conclude.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Dec 2040

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up. * Patient has provided informed consent prior to enrollment. Exclusion Criteria: * No exclusion criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphatic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell chronic lymphocytic leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma childhood acute lymphoblastic leukemia cutaneous melanoma melanoma metastatic melanoma non-Hodgkin lymphoma pediatric lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute lymphatic leukemia B-cell non Hodgkin lymphoma Childhood non-Hodgkin lymphoma Chronic lymphatic leukemia Melanoma stage III Melanoma stage IV Pediatric ALL

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charité Universitätsmedizin Berlin

    RECRUITING

    Berlin, 13353, Germany

  • Uniklinikum Erlangen

    ACTIVE_NOT_RECRUITING

    Erlangen, 91054, Germany

  • Universitäts-Kinderklinik Würzburg

    ACTIVE_NOT_RECRUITING

    Würzburg, 97080, Germany

  • Universitätsklinikum Köln

    ACTIVE_NOT_RECRUITING

    Cologne, 50937, Germany

  • Universitätsklinikum Münster

    RECRUITING

    Münster, 48149, Germany

  • Universitätsklinikum Tübingen

    ACTIVE_NOT_RECRUITING

    Tübingen, 72076, Germany

  • Universitätsmedizin Göttingen

    ACTIVE_NOT_RECRUITING

    Göttingen, 37075, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.